NCT03349255View on ClinicalTrials.gov

Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma

PHASE1TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

October 6, 2017

Primary Completion Date

January 10, 2019

Study Completion Date

January 10, 2019

Conditions
Hepatocellular CarcinomaLiver CancerLiver NeoplasmsMetastatic Liver Cancer
Interventions
BIOLOGICAL

autologous ET1402L1-CART cells

Autologous T cells transduced with lentivirus encoding an anti-AFP (ET1402L1)-CAR expression construct

Trial Locations (1)

430060

Renmin Hospital of Wuhan University, Wuhan

Sponsors

Collaborators (1)

Eureka Therapeutics Inc.
All Listed Sponsors
collaborator

Renmin Hospital of Wuhan University

OTHER

collaborator

Eureka Therapeutics Inc.

INDUSTRY

lead

Aeon Therapeutics (Shanghai) Co., Ltd.

INDUSTRY

NCT03349255 - Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter